進行性遺傳性肝內膽汁淤積 2 型治療市場：依藥物、配銷通路、地區分類

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, By Distribution Channel, and By Region

出版日期: 2023年09月26日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球進行性遺傳性肝內膽汁淤積2型治療市場估計為7,860萬美元，預計在預測期內（2023-2030年）年複合成長率為40.56%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	7860 萬美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	39.80%	2030年市場規模預測	8.188 億美元

圖 1. 2023 年治療 2 型進行性遺傳性肝內膽汁淤積症的全球市場佔有率（按藥物分類）

進行性遺傳性肝內膽汁淤積是指由膽汁分泌機制缺陷引起的一系列罕見遺傳性疾病。通常分為三種亞型：PFIC 1 型、PFIC 2 型和 PFIC 3 型。此疾病通常在生命早期被診斷出來，並經常出現肝內膽汁淤積的徵兆和症狀，例如搔癢、尿色深、糞便蒼白、食慾不振和疲勞。 ABCB11 基因突變是 PFIC2 的原因。 ABCB11 基因提供製造稱為膽鹽輸出幫浦 (BSEP) 的蛋白質的指令。這種蛋白質存在於肝臟中，主要作用是將膽鹽（膽汁的成分）轉運出肝細胞。 ABCB11 基因突變會導致膽鹽在肝細胞中積聚，損害肝細胞並導致肝病。

市場動態

製藥業的主要參與者專注於開發新藥和尋找新的作用機制來治療進行性遺傳性2 型肝內膽汁淤積症。因此，此類新產品的引進預計將在預測期內推動全球進行性遺傳性肝內膽汁淤積2型治療市場的成長。例如，2023年2月14日，生物製藥公司Mirum Pharmaceuticals, Inc.推出了一款治療2個月或以上進行進行性遺傳性肝內膽汁淤積（PFIC）患者膽汁淤積性瘙癢的藥物。我們宣布已提交補充申請LIVMARLI（maralixibat）口服溶液的新藥認證申請（sNDA）。此 sNDA 備案是根據 LIVMARLI 3 月 PFIC sPhase 3 研究的資料。 MARCH PFIC 研究是有史以來規模最大的 PFIC 隨機試驗，招募了 93 名患者，涉及多種遺傳 PFIC 亞型，包括 PFIC1、PFIC2、PFIC3、PFIC4、PFIC6 和突變狀態未知。

本次測試的主要特點

本報告詳細分析了全球進行性遺傳性肝內膽汁淤積2型治療市場，並介紹了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率。
它還闡明了各個細分市場的潛在商機，並解釋了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
本報告根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球進行性遺傳性肝內膽汁淤積 2 型治療市場的主要參與者。
該報告的見解將使行銷人員和公司負責人能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出資訊的決策。
全球進行性遺傳性肝內膽汁淤積 2 型治療市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師。
相關人員可以透過用於分析全球進行性遺傳性肝內膽汁淤積 2 型治療市場的各種策略矩陣來促進決策。

公司簡介
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi SA
- Mylan NV
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
- Jadeite Medicines Inc.
- Ipsen Pharma
- Analyst's Views

第9章章節

參考
調查方法

簡介目錄

Product Code: CMI4399

The global progressive familial intrahepatic cholestasis type 2 treatment market is estimated to be valued at US$ 78.6 Million in 2023 and is expected to exhibit a CAGR of 40.56% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 78.6 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	39.80%	2030 Value Projection:	US$ 818.8 Mn

Figure 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share (%), By Drug, 2023

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - IMG1

Progressive familial intrahepatic cholestasis refers to a collection of rare genetic disorders due to defective mechanisms of bile secretion. Typically divided into three subtypes, PFIC type 1, PFIC type 2, and PFIC type 3. The condition is usually diagnosed in the early years of life and often presents with signs and symptoms of intrahepatic cholestasis, such as pruritis, dark urine, pale stool, loss of appetite, and fatigue. Mutations in the ABCB11 gene are responsible for PFIC2. The ABCB11 gene provides instructions for making a protein called the bile salt export pump (BSEP). The protein is found in the liver, and its main role is to move bile salts (a component of bile) out of liver cells. Mutations in the ABCB11 gene result in the buildup of bile salts in liver cells, damaging these cells and causing liver disease.

Market Dynamics

The key players in the pharmaceutical industry are focusing on the development of new drugs and accessing new mechanisms of action to treat progressive familial intrahepatic cholestasis type 2. Thus, the introduction of such new products into the market is expected to drive growth of the global progressive familial intrahepatic cholestasis type 2 treatment market over the forecast period. For instance, on February 14, 2023, Mirum Pharmaceuticals, Inc., a biopharmaceutical company, announced that the company has submitted a supplemental New Drug Application (sNDA) for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis (PFIC). The sNDA submission is based on data from the March PFIC sPhase 3 study of LIVMARLI. MARCH PFIC is the largest randomized trial conducted in PFIC, with 93 patients across a range of genetic PFIC subtypes, including PFIC1, PFIC2, PFIC3, PFIC4, PFIC6 and unidentified mutational status.

Key features of the study:

This report provides an in-depth analysis of the global progressive familial intrahepatic cholestasis type 2 treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global progressive familial intrahepatic cholestasis type 2 treatments market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Mylan N.V., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Jadeite Medicines Inc., and Ipsen Pharma.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global progressive familial intrahepatic cholestasis type 2 treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive familial intrahepatic cholestasis type 2 treatment market

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Detailed Segmentation:

By Drug:
- Ursodeoxycholic acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi S.A.
- Mylan N.V.
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals
- Jadeite Medicines Inc.
- Ipsen Pharma

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Recent Trends & Key Developments
Regulatory Scenario
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Ursodeoxycholic acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Cholestyramine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Rifampicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

6. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
U.S.
Canada
Europe
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Market Size and Forecast, Y-o-Y Growth By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Mn)
North Africa
Central Africa
South Africa